drugset
drugset / Trial / NCT05150717

ADME Study of [14C]-Jaktinib in Healthy Male Subjects

NCT05150717 ↗

Phase 1 Completed 6 enrolled Suzhou Zelgen Biopharmaceuticals Co.,Ltd
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to evaluate the mass balance and biotransformation after single-dose of \[14C\]-Jaktinib orally in Chinese healthy male subjects.

Timeline

Start
2022-01-04
Primary completion
2022-01-30
Completion
2022-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Jaktinib Unknown 100 mg Oral

Indications

No indication recorded.